Welcome to our dedicated page for MFST news (Ticker: MFST), a resource for investors and traders seeking the latest updates and insights on MFST stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MFST's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MFST's position in the market.
Medifirst Solutions (OTC PINK:MFST) announced its engagement with Shefford Capital Management to formulate and execute a strategic turnaround. CEO Thomas Griffin emphasized the commencement of a new era for the company, shifting focus towards the entertainment production services industry and moving to update SEC filings. Shefford's Managing Director, Jonathan Cross, expressed confidence in Griffin's leadership. Medifirst currently has no significant operations and is undergoing reconstruction, with plans for a shareholder update soon.
Medifirst Solutions (OTC PINK:MFST) announced the appointment of Thomas Griffin as CEO, succeeding in leadership with over 25 years of global entrepreneurial experience. Griffin, recognized for his role in the aviation and finance sectors, is focused on steering the company towards profitability and growth. He aims to redefine the company's future while leveraging recent FDA clearance for the Time Machine TTML-8102000 Laser, designed for pain relief and muscle relaxation. The device promises immediate results with minimal side effects, opening new revenue opportunities for medical professionals.
Medifirst Solutions (OTC: MFST) is set to sponsor a clinical study aimed at enhancing breast cancer surgery outcomes through real-time margin detection using the FLIM diagnostics imaging device. This innovative technology could reduce re-operation rates, which currently affect up to 24% of patients due to unclear margins post-surgery. The study's goal is to achieve 90 to 99% accuracy in confirming cancer-free margins during lumpectomies. Medifirst plans further updates regarding the study and overall company direction in the coming weeks.
FAQ
What is the market cap of MFST (MFST)?
